Abstract Body

Background: Fusion inhibitors bind to gp41 heptad repeat 1 (HR1), inhibiting the formation of six-helix bundle structure and subsequently blocking the entry of HIV-1 inside host cell. Several fusion inhibitors with improved potency and stability, such as C34, SC34 and SC34EK, have been developed and shown higher genetic barrier for resistance induction than Enfuvirtide or T-20, the only FDA approved fusion inhibitor. Here we investigated the effect of mutations to escape from these novel fusion inhibitors on sensitivities against neutralizing antibodies.

Methods: HIV-1JR-FL Env glycoprotein gp160 bearing T-20 resistant mutants (V38A, Q40H and N43D) and C34, SC34, SC34EK resistant mutations (selected by in vitro) in gp41 were constructed. In gp41 mutations are distributed among several functional domains including heptad repeat 1 and 2, MPER, immunodominant region, transmembrane domain and cytoplasmic domain. Pseudoviruses expressing these Env were used in neutralization assay with monoclonal antibodies (MAbs) against CD4 binding site (b12, VRC01, 49G2, 82D5, 42F9), V3 loop (1C10, KD247, 16G6), CD4-induced site (916B2, 4E9C), gp41 membrane proximal external region (4E10, 2F5, 10E8) and gp41 (2E8S34). IC50 value was calculated from neutralization curves and compared with that of wild type virus.

Results: Pseudoviruses expressing resistant mutant envelopes showed reduced level of infectivity when compared to wild type. Our overall neutralization data indicated that fusion inhibitor resistant mutations in gp41 did not reduce neutralization potency of antibodies tested, rather increased the potency of some antibodies. T-20 resistant mutant N43D showed enhanced neutralization by 4E10 (3.5×), 10E8 (12×) and also by anti-V3 antibodies, 1C10 (3.1x) and KD247 (4.3x). SC34EK-resistant virus was significantly sensitive to anti-MPER antibodies (4E10; 22.8x, 2F5; 20.6x, 10E8; 12.4x). MAb 49G2 and 42F9, which fail to neutralize the wild type JR-FL pseudovirus, neutralized C34 and SC34 resistant mutants. Anti-V3 MAbs neutralized C34, SC34 and SC34EK resistant mutants with 3 to 10 fold lower IC50 values than that of wild type.

Conclusions: Our data indicate that, fusion inhibitor resistant mutations in gp41 had impact on major epitopes on gp120 and gp41, enhancing sensitivities to antibodies. Therefore, next generation fusion inhibitors and MAbs could be a potential combination for future regimen of combined antiretroviral therapy.